Skip to main content

Table 4 Outcomes of multivariate analysis to determine risk factors for adverse event of the GMA therapy

From: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

VariableModel 1 (forced entry)Model 2 (backward elimination*)
OR95% CIP valueOR95% CIP value
Patients who received corticosteroid0.3700.168–0.8170.0140.3780.173–0.8270.015
Number of concomitant immunosuppressant medications
0Reference     
12.8151.161–6.8240.0222.7241.131–6.5610.025
23.5591.252–10.1120.0173.3351.187–9.3740.022
≥ 312.8793.303–50.225< 0.00111.7643.091–44.77< 0.001
Paediatric/adolescent patients (≤18 years)2.6011.034–6.5420.0422.0750.926–4.6480.076
Elderly patients (≥65 years)1.3070.611–2.7960.490   
Patients who received GMA retreatment1.1200.518–2.4210.774   
Patients with anaemia (haemoglobin < 10 g/dL)2.1241.088–4.1460.0272.0191.054–3.8670.034
Sex (female)1.5950.835–3.0450.1571.5820.838–2.9840.157
Type of IBD (UC)0.5060.196–1.3080.1600.5190.204–1.3220.169
Duration of disease (year)1.0150.978–1.0540.434   
  1. GMA granulocyte and monocyte adsorptive apheresis, IBD inflammatory bowel disease, UC ulcerative colitis, OR odds ratio, CI confidence interval
  2. *Variables with P > 0.2 were excluded via the backward elimination method